VALPROATE INDUCED HYPERAMMONEMIC ENCEPHALOPATHY

Authors

  • Wajeeha Qayyum Rehman Medical Institute
  • Zaland Ahmed Yousafzai Rehman Medical College Rehman Medical Institute
  • Muhammad Shahid Iqbal Rehman Medical Institute
  • Sohail Khan Rehman Medical Institute
  • Qazi Kamran Amin Rehman Medical Institute
  • Ihtesham Shafiq Rehman Medical Institute

DOI:

https://doi.org/10.55519/JAMC-04-S4-10190

Keywords:

neurology, valporate, encephalopathy

Abstract

Valproate is a commonly prescribed anticonvulsant drug. It has a potential to cause hyperammonemia even in the presence of normal liver function tests. This hyperammonemic state can lead to encephalopathy referred as Valproate induced hyperammonemic encephalopathy (VHE). Here we present a case of valproate induced hyperammonemic encephalopathy in a young male caused by initiation of valproate therapy.

Author Biographies

Wajeeha Qayyum, Rehman Medical Institute

Senior Registrar  Medicine and Allied

Zaland Ahmed Yousafzai, Rehman Medical College Rehman Medical Institute

Inter (House Officer) at Rehman Medical Institute

Muhammad Shahid Iqbal, Rehman Medical Institute

Consultant Neurologist  

Sohail Khan, Rehman Medical Institute

Consultant Neurologist Rehamn Medical Institute

Qazi Kamran Amin, Rehman Medical Institute

Medical Officer Medicine and Allied

Ihtesham Shafiq, Rehman Medical Institute

Trainee PGY 3 General Medicine

References

Sattar Y, Merotto B, Dedousis A, Aadil M, Zil-E-Ali A. Valproic Acid-Induced Hyperammonemia with Encephalopathy (VIHE): A Case Report. J Med Res Innov 2018;2(1):e000108.

Mehta S, Tayabali S, Lachmann R. Valproate-induced hyperammonemia - uncovering an underlying inherited metabolic disorder: a case report. J Med Case Reports 2018;12(1):1–3.

Zafar F, Billadeau BM, Ahmed AU. A Case of Valproate-Induced Hyperammonemic Encephalopathy. Cureus 2020;12(7):e9114.

Shah S, Wang R, Vieux U. Valproate-induced hyperammonemic encephalopathy: a case report. J Med Case Rep 2020;14(1):19.

Baddour E, Tewksbury A, Stauner N. Valproic acid-induced hyperammonemia: incidence, clinical significance, and treatment management. Ment Health Clin 2018;8(2):73–77.

Duman B, Can KC, Ağtaş-Ertan E. Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions. Gen Hosp Psychiatry 2019;59:67–72.

Downloads

Published

2022-10-11